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for each calendar year from January 1, 2000 to December 31, 2005 was performed.
Breast cancer prevalence was determined based on the number of females (21–64
years) having at least one medical services claim with a primary diagnosis of breast 
cancer (ICD-9-CM codes 174, 233.0x, 238.3x, or 239.3x) at any time during the
calendar year. Corresponding medical services use and patterns of treatment were also
reported among females with breast cancer for each year. State Medicaid perspective
was used to calculate costs (2005 US dollars). RESULTS: From 2000 to 2005, the
number of female recipients with breast cancer increased from 789 to 1205, respec-
tively. Female recipients in the age group 45–64 years represented the highest propor-
tion in all the study years, increasing from 78.6% in 2000 to 83.9% in 2005.
Consistent with state population demographics, a majority (90%) of recipients in 
each year were white. Ofﬁ ce visits represented a large majority of medical services 
encounters (98%) and costs (90%) in each year. The average amount per recipient
paid by Medicaid for breast cancer-related medical services use increased from $2637
to $3570 between 2000 and 2005, respectively. The average cost per ofﬁ ce visit 
increased from $255/visit to $429/visit during the same period. CONCLUSIONS:
Breast cancer prevalence increased between 2000 and 2005. There has been a sub-
stantial increase in the cost impact associated with breast cancer on the State Medicaid 
program during the same period.
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OBJECTIVES: To compare dose-reduction patterns in patients with RCC treated
with FDA-approved tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib. 
METHODS: A retrospective analysis was conducted using data from a claims-based 
database (MarketScan MedStat) covering q18 million lives for 2002–2008 in all US
census regions. Patients with q2 claims for RCC (ICD9 189.0 or 198.0), continuous 
health care coverage, 180 days’ coverage before RCC diagnosis, and no claim for 
sorafenib or sunitinib before RCC diagnosis, who received a standard RCC initial
daily dosage of sorafenib 800 mg or sunitinib 50 mg and q2 consecutive dispensings,
were included. Initial episode was deﬁ ned as time from date of ﬁ rst drug-dispensing
to ﬁ rst of switch to another TKI, health care coverage end, treatment end, or 
March 31, 2008. Both patient and patient-time level analyses for dose reductions 
between treatments were conducted. RESULTS: Baseline demographics between
the groups (sorafenib, n  189; sunitinib, n  304) were similar except for a higher 
incidence of stroke (7.9% vs. 3.6%, P  .037) and other cancer site (93.7% vs. 87.8%, 
P  0.036) in the sorafenib group. Signiﬁ cantly more patients receiving sunitinib
required dose reductions compared with sorafenib (ﬁ rst 3 months: 23.0% vs 4.2%; 
complete initial episodes: 35.5% vs 16.9%; P  0.001 for both). For all episodes,
mean time to dose reduction was signiﬁ cantly longer for sorafenib than sunitinib (162
days vs 104 days, P  0.003). Signiﬁ cantly more dose reductions occurred within the
ﬁ rst 3 months with sunitinib than sorafenib (65% vs. 25%, P  0.001). Controlling
for different lengths of exposure time further conﬁ rmed that more dose reductions 
were observed in patients treated with sunitinib than with sorafenib (from 2–6 times 
greater, P  0.001). CONCLUSIONS: This retrospective US claims analysis showed
that signiﬁ cantly more dose reductions, including total number of patients and days,
were required in patients who initially received sunitinib than in those who received 
sorafenib.
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OBJECTIVES: To analyze baseline symptoms, comorbidities, and treatments in newly 
diagnosed RCC patients by age group. METHODS: Retrospective claims-based analy-
sis was conducted using MarketScan MedStat, a database covering all US census
regions, including q18 million lives for years 2002–2008. Patients with initial RCC
diagnosis in 2005–2007, q2 outpatient or q1 inpatient RCC claims (ICD9 189.0 or
198.0), continuous health care coverage, and 180 days coverage before diagnosis 
were included. Patients were followed from diagnosis until health care coverage end 
or June 30, 2008. Conditions, symptoms, and individual Charlson comorbidities were
assessed. Treatment was analyzed using prevalence and time to initiation in patients
 and q65 years old. RESULTS: Of 12,253 patients identiﬁ ed, 61.8% were male (mean 
age, 63 years old) and 51.0% were 65 years old. Overall, pain (59.6%), hypertension
(53.7%), anemia (23.2%), diabetes (23.6%), and chronic kidney disease (19.4%) were
most common comorbidities reported. Most comorbidities were prevalent in q65 years 
old than 65 years old: notably, cerebrovascular disease (8.7% vs. 3%; P  0.001), 
acute myocardial infarction (2% vs 0.7%; P  0.001), and chronic renal failure (9.3% 
vs. 6%; P  0.001). In 65 and q65 groups, most commonly used treatments were 
nephrectomy (53.4% vs. 40.4%; P  .001), intravenous chemotherapy (11.7% vs. 
13.3%; P  0.0079) and oral chemotherapy (10.5% vs. 13.3%; P  0.0001), although 
less than 4% of patients in either group received FDA-approved oral agents sorafenib 
or sunitinib. For 65 and q65 groups, respectively, mean time from RCC diagnosis
to: nephrectomy, 25 and 31 days; radiotherapy, 170 and 177 days; intravenous che-
motherapy, 154 and 181 days; sorafenib, 220 and 247 days; sunitinib, 221 and 205
days. CONCLUSIONS: Baseline comorbidities and symptoms were more common in
RCC patients q65 years old than those 65 years old. Nephrectomy was used more
frequently in patients 65, probably because of comorbidities in older patients. In 
contrast, systemic treatment was similar in both groups.
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OBJECTIVES: The objective of this study was to examine the utilization patterns of 
cancer medications beyond their labeled indications approved by the FDA in commu-
nity oncology practices. METHODS: Drug prescription information from a commu-
nity oncology data warehouse was used for two separate analyses. Patients were
categorized according to whether they had an ICD-9 diagnosis code for one of four 
cancer types including lung, breast, bladder or gastric, and having no other malig-
nancy. The frequency of use of various oncology drugs was examined for each of these 
groups, against a set of medications that were FDA-approved for these indications or 
were recommended by NCCN guidelines. In the second analysis, patients with a single
malignancy, who received any of the ﬁ ve oncology drugs (paclitaxel, vinorelbine,
rituximab, bevacizumab) and gemcitabine, were counted. Comparisons were then 
made against the cancer indications for which these agents were approved by the FDA. 
RESULTS: Seventy-eight percent of breast and 95% of lung cancer patients received
medications approved for these indications, while 68% and 75% also received drugs
that were not approved by the FDA for those conditions. More than 99.7% of these
patients received agents recommended on NCCN guidelines. None of the bladder
cancer patients and only 5% of gastric cancer patients received drugs approved for
these indications, while 97% and 95% of them received guideline-recommended 
drugs. Only half of the patients given paclitaxel or bevacizumab received these for an 
FDA-approved indication. In the case of vinorelbine and gemictabine, the proportion
was lower at 30% and 40% respectively, while it was higher for rituximab at 60%. 
CONCLUSIONS: Oncologists’ choice of drugs is driven by evidence-based guidelines,
independent of FDA approval. There is a high and varying proportion of off-label use 
across oncology medications and cancer types.
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OBJECTIVES: Hepatitis B virus infected over 2 billion people worldwide, and 350 
million suffering from chronic HBV infection. The prevalence of chronic HBV infec-
tion is high in Asia and most of Africa. Kushenin injection as a new traditional Chinese
medicine is now widely used for chronic HBV treatment in China. The objective of 
this study was to compare the effectiveness between Kushenin and western medicines 
on patients with chronic HBV. METHODS:  Based on a pilot study of patient interview 
at one hospital setting, we identiﬁ ed key outcome measurements of effectiveness 
related to Kushenin and western medicine, including ALT recovery rate and negative
conversion rate of HBeAg. Consequently, we performed a systematic literature review 
using computer-based search-engines such as MEDLINE (1966 to 2007), EMBASE 
(1966 to 2006), OVID (1965 to 2006), the Chinese Biomedical Database (CBM) (1978 
to 2006) and CNKI (China National Knowledge Infrastructure) (1994 to 2007). From 
available data, both interferon and lamivudine were selected as western medicines to 
compare with Kushenin regimen. A Meta-analysis was performed using a software
program of Reviewmanager 4.2. RESULTS: A total of 15 published clinical studies 
involving 1396 patients met inclusion criteria for the meta-analysis. Comparing to 
interferon alone regimen, Kushenin showed no signiﬁ cant differences in terms of ALT 
recovery rate [relative risk, RR  0.96; 95% conﬁ dence interval (CIs),0.86–1.09] and 
negative conversion rate of HBeAg (RR  0.85; 95%CIs, 0.69–1.05). Meanwhile, 
kushenin combined with lamivudine showed better effectiveness in term of ALT
recovery rate (RR  1.77; 95%CIs,1.38–2.26) and negative conversion rate of HBeAg 
(RR  2.58; 95% CIs, 1.81–3.68) compared with lamivudine alone. CONCLUSIONS:
Integrated Kushenin plus lamivudine showed better clinical outcomes in ALT recovery
rate and HBeAg negative conversion rate. Further evidence-based analysis is required
due to low quality of randomization procedure in clinical trials and insufﬁ cient study
patients for treating chronic HBV with kunshenin.
